
Rafael Holdings, Inc. – NYSE:RFL
Rafael Holdings stock price today
Rafael Holdings stock price monthly change
Rafael Holdings stock price quarterly change
Rafael Holdings stock price yearly change
Rafael Holdings key metrics
Market Cap | 47.00M |
Enterprise value | N/A |
P/E | -2.4 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | -19.00 |
Price/Book | 0.46 |
PEG ratio | N/A |
EPS | -1.11 |
Revenue | 543K |
EBITDA | -14.42M |
Income | -26.57M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 486.43% |
Oper. margin | 758.72% |
Gross margin | 0% |
EBIT margin | 758.72% |
EBITDA margin | -2657.27% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRafael Holdings stock price history
Rafael Holdings stock forecast
Rafael Holdings financial statements
Apr 2023 | 71K | -1.49M | -2098.59% |
---|---|---|---|
Jul 2023 | 68K | 1.21M | 1792.65% |
Jan 2024 | 68K | 6.04M | 8892.65% |
Apr 2024 | 336K | -32.35M | -9628.27% |
Apr 2023 | 96355000 | 1.46M | 1.52% |
---|---|---|---|
Jul 2023 | 98829000 | 2.2M | 2.23% |
Jan 2024 | 106149000 | 3.89M | 3.67% |
Apr 2024 | 101623000 | 11.06M | 10.89% |
Apr 2023 | -1.31M | 7.38M | -26K |
---|---|---|---|
Jul 2023 | -1.44M | 7.40M | -35K |
Jan 2024 | -2.52M | -2.79M | -932K |
Apr 2024 | -251K | 631K | -30K |
Rafael Holdings alternative data
Aug 2023 | 22 |
---|---|
Sep 2023 | 22 |
Oct 2023 | 22 |
Nov 2023 | 22 |
Dec 2023 | 13 |
Jan 2024 | 13 |
Feb 2024 | 13 |
Mar 2024 | 13 |
Apr 2024 | 13 |
May 2024 | 13 |
Jun 2024 | 13 |
Jul 2024 | 13 |
Rafael Holdings other data
Period | Buy | Sel |
---|---|---|
Aug 2023 | 8000000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | RAFAEL HOLDINGS, INC. 10 percent owner | Common Stock, par value $0.0001 per share | 4,000,000 | $1.25 | $5,000,000 | ||
Purchase | RAFAEL HOLDINGS, INC. 10 percent owner | Common Stock Warrants (Right to Buy) | 4,000,000 | $1.25 | $5,000,000 | ||
Sale | I9 PLUS, LLC 10 percent owner | Class B Common Stock par value $.01 per share | 64,674 | $1.84 | $118,935 | ||
Sale | JONAS HOWARD S director, officer.. | Class B Common Stock, par value $.01 per share | 64,674 | $1.84 | $118,935 | ||
Sale | I9 PLUS, LLC 10 percent owner | Class B Common Stock par value $.01 per share | 14,787 | $1.94 | $28,672 | ||
Sale | JONAS HOWARD S director, officer.. | Class B Common Stock, par value $.01 per share | 14,787 | $1.94 | $28,672 | ||
Sale | I9 PLUS, LLC 10 percent owner | Class B Common Stock par value $.01 per share | 33,100 | $1.93 | $64,015 | ||
Sale | JONAS HOWARD S director, officer.. | Class B Common Stock, par value $.01 per share | 33,100 | $1.93 | $64,015 | ||
Purchase | JONAS HOWARD S director, officer.. | Class B Common Stock, par value $.01 per share | 3,225,806 | $1.86 | $5,999,999 | ||
Purchase | JONAS HOWARD S director, 10 perc.. | Class B Common Stock, par value $.01 per share | 112,561 | $44.92 | $5,056,240 |
Insider | Compensation |
---|---|
Dr. Ameet Mallik (1972) Chief Executive Officer & Director | $2,670,000 |
Mr. William Conkling (1971) Chief Commercial & Bus. Officer | $382,500 |
Mr. Howard S. Jonas (1956) Founder & Chairman | $333,250 |
Mr. David A. Polinsky Esq. (1972) Chief of Staff | $325,000 |
-
What's the price of Rafael Holdings stock today?
One share of Rafael Holdings stock can currently be purchased for approximately $1.49.
-
When is Rafael Holdings's next earnings date?
Unfortunately, Rafael Holdings's (RFL) next earnings date is currently unknown.
-
Does Rafael Holdings pay dividends?
No, Rafael Holdings does not pay dividends.
-
How much money does Rafael Holdings make?
Rafael Holdings has a market capitalization of 47.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 128.32% to 637K US dollars.
-
What is Rafael Holdings's stock symbol?
Rafael Holdings, Inc. is traded on the NYSE under the ticker symbol "RFL".
-
What is Rafael Holdings's primary industry?
Company operates in the Real Estate sector and Real Estate - Services industry.
-
How do i buy shares of Rafael Holdings?
Shares of Rafael Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rafael Holdings's key executives?
Rafael Holdings's management team includes the following people:
- Dr. Ameet Mallik Chief Executive Officer & Director(age: 53, pay: $2,670,000)
- Mr. William Conkling Chief Commercial & Bus. Officer(age: 54, pay: $382,500)
- Mr. Howard S. Jonas Founder & Chairman(age: 69, pay: $333,250)
- Mr. David A. Polinsky Esq. Chief of Staff(age: 53, pay: $325,000)
-
Is Rafael Holdings founder-led company?
Yes, Rafael Holdings is a company led by its founder Mr. Howard S. Jonas.
-
How many employees does Rafael Holdings have?
As Jul 2024, Rafael Holdings employs 13 workers.
-
When Rafael Holdings went public?
Rafael Holdings, Inc. is publicly traded company for more then 7 years since IPO on 27 Mar 2018.
-
What is Rafael Holdings's official website?
The official website for Rafael Holdings is rafaelholdings.com.
-
Where are Rafael Holdings's headquarters?
Rafael Holdings is headquartered at 520 Broad Street, Newark, NJ.
-
How can i contact Rafael Holdings?
Rafael Holdings's mailing address is 520 Broad Street, Newark, NJ and company can be reached via phone at +212 6581450.
Rafael Holdings company profile:

Rafael Holdings, Inc.
rafaelholdings.comNYSE
13
Real Estate - Services
Real Estate
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Newark, NJ 07102
CIK: 0001713863
ISIN: US75062E1064
CUSIP: 75062E106